# Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)

> **NCT07642557** · — · RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 470 (estimated)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07642557
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-04
- **Primary completion:** 2029-05-31
- **Final completion:** 2029-05-31
- **Target enrollment:** 470 (ESTIMATED)
- **Last updated:** 2026-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07642557

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07642557, "Remibrutinib in Real-world Clinical Practice - a Germany Sub-study (REASSERT)". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07642557. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*